- Home
- DNTH
as 09-15-2025 4:00pm EST
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $61.57 | AVG Volume (30 days): | 969.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.37 - $38.59 | Next Earning Date: | 11-06-2025 |
| Revenue: | $4,854,000 | Revenue Growth: | 17.87% |
| Revenue Growth (this year): | -53.25% | Revenue Growth (next year): | -13.24% |
Stock Insider Trading Activity of Dianthus Therapeutics Inc. (DNTH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Savitz Ryan | DNTH | CFO & CBO | Sep 9 '25 | Sell | $35.00 | 20,000 | $700,000.00 | 0 |
Latest Dianthus Therapeutics Inc. News
DNTH Breaking Stock News: Dive into DNTH Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise
MT Newswires
3 days ago
Stifel Adjusts Price Target on Dianthus Therapeutics to $65 From $52, Maintains Buy Rating
MT Newswires
3 days ago
Wedbush Raises Price Target on Dianthus Therapeutics to $44 From $42, Keeps Outperform Rating
MT Newswires
4 days ago
Dianthus Therapeutics Closes Upsized $288 Million Offering
GlobeNewswire
4 days ago
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
MT Newswires
5 days ago
Dianthus Therapeutics Prices Upsized $251 Million Securities Offering
GlobeNewswire
6 days ago
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
Insider Monkey
6 days ago
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential
Compare DNTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNTH Dianthus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.